Group 1: R&D and Innovation - R&D expenses decreased in the first three quarters of 2025, aligned with the company's established research plans and progress [1] - The company leverages resources from its Yunnan Province plant extraction laboratory and research institutes in Japan and France to conduct targeted research in various areas, including innovative raw material development and functional cosmetics [1] Group 2: Competitive Advantage - The company's core competitive advantage is a brand trust barrier formed by "medical endorsement + consumer mindset," which is difficult to replicate in the short term [2] - This trust is built on years of deep engagement with hospital channels, professional doctor recognition, and extensive clinical validation data, resulting in a large, loyal customer base of sensitive skin users [2] Group 3: Profitability Improvement - The company's product profitability has improved, primarily due to a focus on brand building and member operation strategies [2] - Strategies include differentiated member operations, maintaining stable pricing, reducing promotional benefits, and streamlining product lines to concentrate resources on core products [2]
贝泰妮(300957) - 2025年12月投资者关系活动记录表